{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:40:55Z","timestamp":1791103255671,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2007,11,29]],"date-time":"2007-11-29T00:00:00Z","timestamp":1196294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2007,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate whether etanercept has a steroid\u2010sparing effect in the treatment of patients with relapsing polymyalgia rheumatica (PMR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study group comprised patients with relapsing PMR who were not able to reduce their prednisone dosage below 7.5\u201310 mg\/day and who had experienced corticosteroid\u2010related side effects. Patients received injections of etanercept 25 mg twice weekly for 24 weeks, and were followed up for 3 additional months after treatment withdrawal. Patients regularly underwent clinical assessment, measurement of erythrocyte sedimentation rate and C\u2010reactive protein level, and ultrasound (US) examination of the shoulders during the 9 months of the followup period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All 6 enrolled patients responded to etanercept with sustained remission (improvement of at least 70% according to European League Against Rheumatism response criteria for PMR in 4 patients and at least 50% in 2 patients) and were able to significantly reduce their median prednisone daily dosage without experiencing a disease relapse (8.75 mg versus 2.5 mg; <jats:italic>P<\/jats:italic> = 0.026) at the end of the 9\u2010month study period. US shoulder examination performed at the end of followup demonstrated a parallel reduction of glenohumeral and periarticular inflammation. A significant reduction in the cumulative prednisone dose 9 months before versus the 9\u2010month study period was observed (mean \u00b1 SD 1,767 \u00b1 524 mg versus 730 \u00b1 182 mg; <jats:italic>P<\/jats:italic> = 0.028). Three patients developed nonsevere side effects: bacterial cystitis in 2 and influenza in 1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results, which should be confirmed in a controlled study, suggest that etanercept may be a safe and useful corticosteroid\u2010sparing agent in relapsing PMR.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.23095","type":"journal-article","created":{"date-parts":[[2007,11,29]],"date-time":"2007-11-29T16:47:03Z","timestamp":1196354823000},"page":"1514-1519","source":"Crossref","is-referenced-by-count":45,"title":["Treatment of refractory polymyalgia rheumatica with etanercept: An open pilot study"],"prefix":"10.1002","volume":"57","author":[{"given":"Maria Grazia","family":"Catanoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Macchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Pipitone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,11,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra011913"},{"key":"e_1_2_6_3_2","first-page":"276","article-title":"Diagnostic approach in a patient presenting with polymyalgia","volume":"17","author":"Gonzalez\u2010Gay MA","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6721.344"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1986.tb02796.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W"},{"key":"e_1_2_6_7_2","first-page":"205","article-title":"Polymyalgia rheumatica and giant cell arteritis: a 5\u2010year epidemiologic and clinical study in Reggio Emilia, Italy","volume":"5","author":"Salvarani C","year":"1987","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401022"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.4.218"},{"key":"e_1_2_6_10_2","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli G","year":"1996","journal-title":"J Rheumatol"},{"issue":"4","key":"e_1_2_6_11_2","first-page":"S58","article-title":"Steroid sparing therapeutic approaches to polymyalgia rheumatica\u2010giant cell arteritis: state of the art and perspectives","volume":"18","author":"Ferraccioli GF","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-7-200410050-00005"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707173370301"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"e_1_2_6_20_2","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study","volume":"30","author":"Salvarani C","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_21_2","first-page":"373","article-title":"TNF\u2010alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and\/or osteoporosis: a seven cases report","volume":"9","author":"Migliore A","year":"2005","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(84)90012-X"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_25_2","first-page":"2179","article-title":"The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain","volume":"27","author":"Gonzalez\u2010Gay MA","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_26_2","first-page":"123","article-title":"The Italian version of the Functional Disability Index of the Health Assessment Questionnaire: a reliable instrument for multicenter studies on rheumatoid arthritis","volume":"11","author":"Ranza R","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.011379"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.002618"},{"key":"e_1_2_6_29_2","first-page":"1049","article-title":"Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case\u2010control study","volume":"28","author":"Cantini F","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20901"},{"key":"e_1_2_6_31_2","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica","volume":"32","author":"Kremers HM","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_6_32_2","first-page":"1326","article-title":"The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10\u2010year study","volume":"26","author":"Gonzalez\u2010Gay MA","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.051979"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00005"},{"key":"e_1_2_6_35_2","first-page":"225","article-title":"Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF\u2010alpha antibody with the interleukin\u20101 receptor antagonist","volume":"6","author":"Butler DM","year":"1995","journal-title":"Eur Cytokine Netw"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.23095","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.23095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T15:59:28Z","timestamp":1696780768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.23095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,29]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,12,15]]}},"alternative-id":["10.1002\/art.23095"],"URL":"https:\/\/doi.org\/10.1002\/art.23095","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,29]]}}}